{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:23Z","timestamp":1791443003928,"version":"4.3.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jad.2025.120084","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:34:51Z","timestamp":1755808491000},"page":"120084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysis"],"prefix":"10.1016","volume":"392","author":[{"given":"James R.","family":"O'Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120084_bb0005","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-020-00455-y","article-title":"Population pharmacokinetics of sertraline in healthy subjects: a model-based meta-analysis","volume":"22","author":"Alhadab","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.jad.2025.120084_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.104077","article-title":"Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis","volume":"3","author":"Amann","year":"2024","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.jad.2025.120084_bb0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/00912700122010159","article-title":"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe","volume":"41","author":"Amchin","year":"2001","journal-title":"J. Clin. Pharma"},{"key":"10.1016\/j.jad.2025.120084_bb0020","series-title":"Escitalopram 10mg Tablets","author":"Aurobindo Pharma","year":"2024"},{"key":"10.1016\/j.jad.2025.120084_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01533-1","article-title":"Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report","volume":"11","author":"Braund","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.120084_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0169-2607(00)00124-3","article-title":"A step-by-step guide to non-linear regression analysis of experimental data using a Microsoft excel spreadsheet","volume":"65","author":"Brown","year":"2001","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.jad.2025.120084_bb0035","series-title":"Stopping Antidepressants","author":"Burn","year":"2024"},{"key":"10.1016\/j.jad.2025.120084_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.107143","article-title":"The costs incurred by the NHS in England due to the unnecessary prescribing of dependency-forming medications","volume":"125","author":"Davies","year":"2022","journal-title":"Addict. Behav."},{"key":"10.1016\/j.jad.2025.120084_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jad.2025.120084_bb0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline","volume":"41","author":"DeVane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2025.120084_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25690","article-title":"Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT","volume":"25","author":"Duffy","year":"2021","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.jad.2025.120084_bb0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.euroneuro.2017.06.009","article-title":"Escitalopram plasma levels and antidepressant response","volume":"27","author":"Florio","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0065","series-title":"Celexa (citalopram hydrobromide) Tablets\/Oral Solution","author":"Forest Pharmaceuticals Inc.","year":"2009"},{"key":"10.1016\/j.jad.2025.120084_bb0070","doi-asserted-by":"crossref","DOI":"10.1177\/2045125321991274","article-title":"What i have learnt from helping thousands of people taper off antidepressants and other psychotropic medications","volume":"11","author":"Framer","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0075","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1503\/cmaj.160991","article-title":"Antidepressant discontinuation syndrome","volume":"189","author":"Gabriel","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.jad.2025.120084_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211039327","article-title":"Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study","volume":"11","author":"Groot","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.120084_bb0090","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bjp.0706108","article-title":"Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors","volume":"144","author":"Hirano","year":"2005","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0095","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms","volume":"6","author":"Horowitz","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.120084_bb0100","series-title":"The Maudsley Deprescribing Guidelines in Psychiatry: Antidepressants, Benzodiazepines, Gabapentinoids and z-Drugs","author":"Horowitz","year":"2024"},{"key":"10.1016\/j.jad.2025.120084_bb0105","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","article-title":"A method for tapering antipsychotic treatment that may minimise the risk of relapse","volume":"47","author":"Horowitz","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2025.120084_bb0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","article-title":"Estimating risk of antidepressant withdrawal from a review of published data","volume":"37","author":"Horowitz","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2025.120084_bb0115","unstructured":"Horowitz, M., Cooper, R., Moncrieff, J., Read, J., n.d. Methods used to reduce and Stop antidepressants on peer-led forums: results from a global survey. Unpublished."},{"key":"10.1016\/j.jad.2025.120084_bb0120","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/jcph.1927","article-title":"Prediction of fluoxetine and norfluoxetine pharmacokinetic profiles using physiologically based pharmacokinetic modeling","volume":"61","author":"Jeong","year":"2021","journal-title":"J. Clin. Pharma"},{"key":"10.1016\/j.jad.2025.120084_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0091270009337946","article-title":"Effect of age, weight, and CYP2C19 genotype on escitalopram exposure","volume":"50","author":"Jin","year":"2010","journal-title":"J. Clin. Pharma"},{"key":"10.1016\/j.jad.2025.120084_bb0130","unstructured":"Kaplan, E.M. Antidepressant noncompliance as a factor in the discontinuation syndrome. J. Clin. Psychiatry 1997 58 Suppl 7, 31-35; discussion 36."},{"key":"10.1016\/j.jad.2025.120084_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: clinical pharmacokinetics and drug interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2025.120084_bb0140","series-title":"PharmaCalc v02","author":"Kramer","year":"2013"},{"key":"10.1016\/j.jad.2025.120084_bb0145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00705.x","article-title":"Distribution and excretion of sertraline and N-desmethylsertraline in human milk","volume":"45","author":"Kristensen","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0150","series-title":"Duloxetine 20mg Gastro-resistant Capsules","author":"Krka UK Ltd","year":"2023"},{"key":"10.1016\/j.jad.2025.120084_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smrv.2012.08.001","article-title":"Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications","volume":"17","author":"Krystal","year":"2013","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.jad.2025.120084_bb0160","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2106356","article-title":"Maintenance or discontinuation of antidepressants in primary care","volume":"385","author":"Lewis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.120084_bb0165","series-title":"Sertraline 50 Mg Tablets - Summary of Product Characteristics","author":"Lupin Healthcare","year":"2023"},{"key":"10.1016\/j.jad.2025.120084_bb0170","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [ 11 C]DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"AJP"},{"key":"10.1016\/j.jad.2025.120084_bb0175","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881108093582","article-title":"Problems associated with long-term treatment with selective serotonin reuptake inhibitors","volume":"23","author":"Moret","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0180","author":"National Institute Health and Care Excellence (NICE)"},{"key":"10.1016\/j.jad.2025.120084_bb0185","series-title":"Prescription Cost Analysis \u2013 England 2023\/24","author":"NHS Business Services Authority","year":"2024"},{"key":"10.1016\/j.jad.2025.120084_bb0190","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2025.10831","article-title":"Correlations between receptor occupancy change and mental state in patients using long-acting injectable antipsychotics: the MIDILIA pilot study","author":"O'Neill","year":"2025","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jad.2025.120084_bb0195","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.2174\/138161212803523699","article-title":"Therapeutic drug monitoring for antidepressant drug treatment","volume":"18","author":"Ostad Haji","year":"2012","journal-title":"CPD"},{"key":"10.1016\/j.jad.2025.120084_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2025.120084_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00213-013-3146-1","article-title":"Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers","volume":"230","author":"Sato","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120084_bb0210","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00213-007-0877-x","article-title":"Receptor occupancy of mirtazapine determined by PET in healthy volunteers","volume":"195","author":"Smith","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120084_bb0215","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211067656","article-title":"Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review","volume":"12","author":"S\u00f8rensen","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41380-021-01285-w","article-title":"The relationship between dose and serotonin transporter occupancy of antidepressants\u2014a systematic review","volume":"27","author":"S\u00f8rensen","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120084_bb0225","series-title":"Dependence and Withdrawal Associated With Some Prescribed Medicines: An Evidence Review","author":"Taylor","year":"2019"},{"key":"10.1016\/j.jad.2025.120084_bb0230","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-200038060-00001","article-title":"Clinical pharmacokinetics of mirtazapine","volume":"38","author":"Timmer","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2025.120084_bb0235","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1002\/hup.470100803","article-title":"Bioavailability of mirtazapine from Remeron\u00ae tablets after single and multiple oral dosing","volume":"10","author":"Voortman","year":"1995","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jad.2025.120084_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.978202","article-title":"Joint population pharmacokinetic modeling of venlafaxine and O-desmethyl venlafaxine in healthy volunteers and patients to evaluate the impact of morbidity and concomitant medication","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0245","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2146\/ajhp050006","article-title":"Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor","volume":"62","author":"Westanmo","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jad.2025.120084_bb0250","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/2045125315612334","article-title":"A review of the management of antidepressant discontinuation symptoms","volume":"5","author":"Wilson","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120084_bb0255","series-title":"EFFEXOR XR - Venlafaxine Hydrochloride Capsule, Extended Release","author":"Wyeth Pharmaceuticals, Inc.","year":"2008"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725015265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725015265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:02:30Z","timestamp":1780203750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725015265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S0165032725015265"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120084","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120084"}}